DURECT (DRRX) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• DURECT Corporation (NASDAQ: DRRX) is set to announce its Q2 2025 earnings on August 12th, with analysts predicting a loss of $0.13 per share and revenue of $0.32 million.
• The stock recently traded down by 0.5%, closing at $1.85, and has a market cap of approximately $57.43 million.
• Analysts at Wall Street Zen initiated coverage with a "sell" rating, while Northland Capital Markets downgraded DURECT from "strong-buy" to "hold".

DURECT (NASDAQ:DRRX - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $0.32 million for the quarter.

DURECT Trading Down 0.5%

Shares of DURECT stock traded down $0.01 on Friday, hitting $1.87. The stock had a trading volume of 139,725 shares, compared to its average volume of 2,894,182. The company's 50 day moving average price is $0.83 and its 200 day moving average price is $0.77. The stock has a market cap of $58.04 million, a price-to-earnings ratio of -12.47 and a beta of 0.83. DURECT has a 52-week low of $0.48 and a 52-week high of $2.64.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Northland Capmk cut DURECT from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 29th. Wall Street Zen began coverage on DURECT in a research note on Thursday, May 22nd. They issued a "sell" rating for the company.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.